Jeevan Larson's questions to ANI Pharmaceuticals Inc (ANIP) leadership • Q4 2024
Question
On behalf of Les Sulewski, Jeevan Larson of Truist Securities asked about potential disruptions to the Cortrophin market, specifically inquiring about the threat from synthetic versions or other competitors.
Answer
Executive Nikhil Lalwani responded that the ACTH market is in a strong growth phase, with patient numbers still well below historical peaks, indicating a large opportunity. He highlighted that 40% of ANI's prescribers are new to the ACTH category, demonstrating market expansion. He also noted that bringing a generic or biosimilar to market is historically difficult and that the competitive landscape is expected to remain a two-player market focused on building awareness.